Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 9;5(21):4406-4412.
doi: 10.1182/bloodadvances.2021005076.

Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy

Arushi Dhar  1 , Tung Ming Leung  2 , Abena Appiah-Kubi  3 , Dorota Gruber  2 , Banu Aygun  3 , Olivia Serigano  4 , Elizabeth Mitchell  1
Affiliations

Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy

Arushi Dhar et al. Blood Adv. .

Abstract

Cardiac abnormalities such as left ventricular hypertrophy, left ventricular dilation, and pulmonary hypertension in sickle cell anemia have been previously described. Hydroxyurea, a disease-modifying therapy for sickle cell anemia, has been used for several decades. Longitudinal assessment of echocardiographic abnormalities in children and young adults with sickle cell anemia receiving hydroxyurea therapy is lacking. The goal of this retrospective study was to determine the prevalence of echocardiographic abnormalities in children and young adults with sickle cell anemia and to examine the effects of hydroxyurea on reverse cardiac remodeling. We reviewed the records of patients with sickle cell anemia who underwent routine cardiac screening at Cohen Children's Medical Center between 2010 and 2017, followed by retrospective longitudinal analysis of echocardiograms performed on patients receiving treatment with hydroxyurea. Data on a total of 100 patients with sickle cell anemia were analyzed; 60 (60%) were being treated with hydroxyurea. Twenty-five (41.6%) of the patients on hydroxyurea had been treated for <1 year; these patients had a significantly greater prevalence of left ventricular dilation compared with those who had been on treatment for >1 year. Serial echocardiograms of patients receiving hydroxyurea were then analyzed. Left ventricular dilation and hypertrophy improved significantly with hydroxyurea treatment. In addition, the left ventricular volume and mass correlated negatively with duration of treatment with hydroxyurea. Our study provides evidence that prolonged hydroxyurea therapy may lead to reverse cardiac remodeling. Future studies should attempt to follow up this patient cohort for a longer duration.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
LVEDv vs duration of treatment with HU (Spearman correlation).
Figure 2.
Figure 2.
LV mass vs duration of treatment with HU (Spearman correlation).
See this image and copyright information in PMC

References

    1. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11):762-769. - PubMed
    1. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340(13):1021-1030. - PubMed
    1. Gladwin MT, Vichinsky E.. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359(21):2254-2265. - PubMed
    1. Rees DC, Williams TN, Gladwin MT.. Sickle-cell disease. Lancet. 2010;376(9757):2018-2031. - PubMed
    1. Grossman W, Jones D, McLaurin LP.. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56(1):56-64. - PMC - PubMed